<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58838">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02086734</url>
  </required_header>
  <id_info>
    <org_study_id>CTP NK 2012</org_study_id>
    <nct_id>NCT02086734</nct_id>
  </id_info>
  <brief_title>Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients With Metastasized Renal Cell Carcinoma</brief_title>
  <official_title>Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients With Metastasized Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Siemens Healthcare Diagnostics Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is the evaluation of dynamic contrast-enhanced CT (Perfusion-CT)
      for therapeutic response predicition in patients with metastasized renal carcinoma (mRCC)
      undergoing antiangiogenetic therapy (AAT) with multikinase inhibitors.

      In this study patients with mRCC under AAT will be examined with 3 serial Perfusion - CT
      scans - partially intergrated in their regular staging CT scheme - at baseline (before AAT
      start),  1 week after AAT as well as 8 weeks after AAT initialization. Thereby selected
      intrabdomial or intrathoracic metastases will be monitored longitudinally with perfusion CT.
      Pretreament and post-treament perfusion characteristics of the assessed metastatic lesions
      will be quantified and correlated with patient outcome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Prediction of progression-free interval and overall survival after initialization of antiangiogenic therapy based on baseline values and relative changes of CT perfusion parameters</measure>
    <time_frame>up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of CT perfusion parameters at baseline as well as their relative changes after start of antiangiogenic therapy with response status according to RECIST 1.1</measure>
    <time_frame>up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Metastatic Renal Cancer</condition>
  <arm_group>
    <arm_group_label>mRCC patients assessed with Perfusion CT</arm_group_label>
    <description>Study population consists of patients with metastasized renal cancer eligible for AAT with either Sunitinib (Sutent®), Pazopanib (Votrient ®), Sorafenib (Nexavar®) evaluated with Perfusion-CT</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Perfusion-CT</intervention_name>
    <description>Baseline Perfusion CT-Scan (before AAT)
Follow-Up I Perfusion-CT Scan 7 days after start with AAT
Follow-Up II Perfusion-CT Scan 8 weeks after start with AAT</description>
    <arm_group_label>mRCC patients assessed with Perfusion CT</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with metastatic renal cell cancer eligible for AAT (antiangiogenic therapy) with
        either Sunitinib (Sutent®), Pazopanib (Votrient ®), Sorafenib (Nexavar®)   presenting at
        the Departement of Urology. LMU, meeting the inclusion/exclusion criteria
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with metastasized renal cell carcinoma treated at the Department of Urology
        (University of Munich - Grosshadern Campus)

        1)  with either - Sunitinib (Sutent®),   Pazopanib (Votrient ®) bzw. Sorafenib (Nexavar®)
        as first-line therapy

        2.)  with Sunitinib (Sutent®),   Pazopanib (Votrient ®) bzw. Sorafenib (Nexavar®) as
        second-line therapy after failed first-line therapy, who are off therapy for at least 2
        weeks

        and who have given informed consent to participate in the study

        Exclusion Criteria:

        Patients who have:

          -  not given informed consent

          -  known iodine allergy

          -  high grade renal insuffiency (eGFR &lt; 30ml/min) not on dialysis

          -  overt hyperthyreoidism

          -  singular metastases &lt;1cm in diameter

          -  an increase of their baseline creatine levels of &gt;20% between CT examinations
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Staehler, PD Dr. med.</last_name>
    <role>Study Chair</role>
    <affiliation>Urologische Klinik und Poliklinik der Universität München</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anno Graser, PD Dr. med.</last_name>
    <role>Study Director</role>
    <affiliation>Institut für Klinische Radiologie des Klinikums der Universität München</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander Sterzik, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut für Klinische Radiologie des Klinikums der Universität München</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jozefina Casuscelli, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Urologische Klinik und Poliklinik der Universität München</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander Sterzik, Dr. med.</last_name>
    <phone>+4989/7095-0</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Urologische Klinik und Poliklinik der Universität München</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jozefina Casuscelli, Dr. med.</last_name>
      <phone>+4989/7095-0</phone>
      <email>jozefina.casuscelli@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Alexander Sterzik, Dr. med.</last_name>
      <phone>+4989/7095-0</phone>
      <email>alexander.sterzik@med.uni-muenchen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Jozefina Casuscelli, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Sterzik, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katharina Hellbach, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martina Karpitschka, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Ingrisch, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 11, 2014</lastchanged_date>
  <firstreceived_date>November 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Dr. Jozefina Casuscelli</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Perfusion-CT</keyword>
  <keyword>mRCC</keyword>
  <keyword>antiangiogenic therapy</keyword>
  <keyword>response assessment</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angiogenesis Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
